ACLY blockade rewires tumor metabolism to boost immunity in MASH-driven hepatic cell carcinoma
Open Access
- 24 January 2026
- journal article
- Published by Elsevier in Journal of the National Cancer Center
- Vol. 6 (1) , 8-10
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesisNature Immunology, 2025
- ACLY inhibition promotes tumour immunity and suppresses liver cancerNature, 2025
- Targeting Treg–fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinomaGut, 2025
- Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-BevacizumabLiver Cancer, 2025
- Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapyGut, 2024
- Prognostic Implications of MRI-assessed Intratumoral Fat in Hepatocellular Carcinoma: An Asian and European Cohort StudyRadiology, 2024
- Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinomaGut, 2024
- Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinomaHepatology, 2022
- Immunotherapies for hepatocellular carcinomaNature Reviews Clinical Oncology, 2021
- NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature, 2021